US 11,744,874 B2
Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof
David Stover, Encino, CA (US); Dhruba Bharali, Sherman Oaks, CA (US); Bruce A Hay, Niskayuna, NY (US); and Tahmineh Safaie, Los Angeles, CA (US)
Assigned to Nammi Therapeutics, Inc., Los Angeles, CA (US)
Filed by Nammi Therapeutics, Inc., Los Angeles, CA (US)
Filed on Dec. 21, 2020, as Appl. No. 16/974,306.
Claims priority of provisional application 62/974,746, filed on Dec. 20, 2019.
Prior Publication US 2021/0187066 A1, Jun. 24, 2021
Int. Cl. A61K 47/54 (2017.01); A61K 47/69 (2017.01); A61K 31/4164 (2006.01); A61K 38/17 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/177 (2013.01) [A61K 45/06 (2013.01); A61K 47/543 (2017.08); A61K 47/6911 (2017.08)] 9 Claims
OG exemplary drawing
 
1. A Toll-like receptor (TLR) prodrug composition comprising TR6 as the TLR prodrug, TR6 having the following structure:

OG Complex Work Unit Chemistry